ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: EARLY PRURITUS RESPONSES FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2

被引：0

作者：

Stander, Sonja ^{[1
]}

Yosipovitch, Gil ^{[2
]}

Silverberg, Jonathan I. ^{[3
]}

Simpson, Eric L. ^{[4
]}

Sinclair, Rodney ^{[5
]}

Su, John C. ^{[6
,7
,8
]}

Kerkmann, Urs ^{[9
]}

Gallardo, William Romero ^{[10
]}

Valdez, Hernan ^{[11
]}

Rojo, Ricardo ^{[12
]}

Biswas, Pinaki ^{[13
]}

Farooqui, Saleem A. ^{[14
]}

机构：

[1] Munster Univ Hosp, Dept Dermatol, Ctr Chron Pruritus, Munster, Germany

[2] Univ Miami, Miller Sch Med, Miami Itch Ctr, Miami, FL USA

[3] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA

[4] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

[5] Sinclair Dermatol, East Melbourne, Vic, Australia

[6] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Populat Allergy, Parkville, Vic, Australia

[7] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Dermatol, Parkville, Vic, Australia

[8] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Paediat, Parkville, Vic, Australia

[9] Pfizer Pharma GmbH, Global Med Affairs Inflammat & Immunol, Berlin, Germany

[10] Pfizer Ltd, Global Med Affairs Inflammat & Immunol, Surrey, England

[11] Pfizer Inc, Global Prod Dev Inflammat & Immunol, New York, NY USA

[12] Pfizer Inc, Global Prod Dev Inflammat & Immunol, Groton, CT USA

[13] Pfizer Inc, Biostat, New York, NY USA

[14] Pfizer Ltd, Clin Dev & Operat, Surrey, England

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

PT13

引用

页码：56 / 56

页数：1

共 50 条

[31] Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial
Yao, Zhirong
Xu, Aie
He, Li
Ding, Yangfeng
Hu, Guohong
Vyas, Shefali
Wang, Bo
Luo, Xin
Li, Shiqi
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II23 - II24
[32] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial
Li, Hang
Cheng, Hao
Lu, Qianjin
Lai, Wei
Tao, Xiaohua
Encinas, Gerardo A.
Vyas, Shefali
Wang, Bo
Luo, Xin
Li, Shiqi
CHINESE MEDICAL JOURNAL, 2024, 137 (16) : 1991 - 1992
[33] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial
Li Hang
Cheng Hao
Lu Qianjin
Lai Wei
Tao Xiaohua
Encinas Gerardo A
Vyas Shefali
Wang Bo
Luo Xin
Li Shiqi
中华医学杂志英文版, 2024, 137 (16)
[34] Abrocitinib in the treatment of moderate-to-severe atopic dermatitis refractory to dupilumab treatment: An analysis of JADE-EXTEND, a phase 3 long-term extension study
Shi, Vivian
Bhutani, Tina
Deleuran, Mette
Fonacier, Luz
Shumack, Stephen
Zhang, Fan
Cameron, Michael C.
Chan, Gary
Valdez, Hernan
Yin, Natalie
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB36 - AB36
[35] Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Blauvelt, Andrew
Silverberg, Jonathan, I
Lynde, Charles W.
Bieber, Thomas
Eisman, Samantha
Zdybski, Jacek
Gubelin, Walter
Simpson, Eric L.
Valenzuela, Fernando
Criado, Paulo Ricardo
Lebwohl, Mark G.
Feeney, Claire
Khan, Tahira
Biswas, Pinaki
DiBonaventura, Marco
Valdez, Hernan
Cameron, Michael C.
Rojo, Ricardo
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 104 - 112
[36] Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
Gooderham, Melinda J.
Weidinger, Stephan
Simpson, Eric L.
Deleuran, Mette
Gold, Linda F. Stein
Farooqui, Saleem A.
Biswas, Pinaki
Chan, Gary
Guler, Erman
Koppensteiner, Herwig
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II32 - II33
[37] Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study
McMichael, Amy
Cork, Michael
Teng, Joyce
Rojo, Ricardo
Valdez, Hernan
Zhang, Fan
Myers, Daniela
Chan, Gary
DiBonaventura, Marco
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB156 - AB156
[38] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial
Li, Hang
Cheng, Hao
Lu, Qianjin
Lai, Wei
Tao, Xiaohua
Encinas, Gerardo A.
Vyas, Shefali
Wang, Bo
Luo, Xin
Li, Shiqi
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[39] Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program
Paller, Amy
Eichenfield, Lawrence F.
Cork, Michael J.
Bangert, Christine
Irvine, Alan D.
Weidinger, Stephan
Johnson, Susan
Lazariciu, Irina
Koppensteiner, Herwig
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 77
[40] Onset and depth of response with abrocitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the phase IIIb JADE DARE clinical trial
Reich, K.
Valenzuela, F.
Hong, H. C.
Eyerich, K.
Rice, Z. Pressley
Bhambri, A.
Guler, E.
Zhang, F.
Rojo, R.
Chan, G.
Clibborn, C.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E170 - E170

← 1 2 3 4 5 →